Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression
NCT07168083
·
clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
22
Enrollment
OTHER
Sponsor class
Conditions
Ovarian Cancer
Antibody-drug Conjugates
Clear Cell Adenocarcinoma of Ovary
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University